Shock Syndromes II

1011.e1. https://doi.org/10.1016/j.ajo.2008.12.040

Bastuji-Garin S, Rzany B, Stern RS, Shear NH,

Naldi L, Roujeau JC. Clinical classification of cases

of toxic epidermal necrolysis, Stevens-Johnson syn-

drome, and erythema multiforme. Arch Dermatol.

1993;129(1):92-96.

Kim DH, Yoon KC, Seo KY, et al. The role of systemic

immunomodulatory treatment and prognostic factors on

chronic ocular complications in Stevens-Johnson syn-

drome. Ophthalmology. 2015;122(2):254-264. https://

doi.org/10.1016/j.ophtha.2014.08.013

Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC,

Mockenhaupt M. Effects of treatments on the mortal-

ity of Stevens-Johnson syndrome and toxic epidermal

necrolysis: a retrospective study on patients included

in the prospective EuroSCAR study. J Am Acad

Dermatol. 2008;58(1):33-40. https://doi.org/10.1016/j.

jaad.2007.08.039

Sekula P, Dunant A, Mockenhaupt M, et al.

Comprehensive survival analysis of a cohort of patients

with Stevens-Johnson syndrome and toxic epidermal

necrolysis. J Invest Dermatol. 2013;133(5):1197-1204.

https://doi.org/10.1038/jid.2012.510

Seminario-Vidal L, Kroshinsky D, Malachowski SJ,

et al. Society of Dermatology Hospitalists supportive

care guidelines for the management of Stevens-Johnson

syndrome/toxic epidermal necrolysis in adults. J Am

Acad

Dermatol.

2020;82(6):1553-1567.

https://doi.

org/10.1016/j.jaad.2020.02.066

Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng

WJ. High-dose intravenous immunoglobulin in the

treatment of toxic epidermal necrolysis: a study of ocu-

lar benefits. Eye (Lond). 2005;19(8):846-853. https://doi.

org/10.1038/sj.eye.6701653

Zimmermann S, Sekula P, Venhoff M, et al. Systemic

immunomodulating therapies for Stevens-Johnson syn-

drome and toxic epidermal necrolysis: a systematic review

522. https://doi.org/10.1001/jamadermatol.2016.5668